Ovid Therapeutics Inc. is a New York-based biotech company using its BoldMedicine® approach to develop medicines that transform the lives of people affected by rare neurological disorders. Ovid seeks to couple deep CNS experience with emerging advances in genetics and the pathways of the brain to build a leading neuroscience pipeline. For more information, please visit www.ovidrx.com. Review our community guidelines: http://www.ovidrx.com/community-guidelines/
Location: United States, New York
Employees: 11-50
Total raised: $103.2M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.02.2019 | - | $28.2M | - |
| 11.08.2015 | Series B | $75M | - |
Mentions in press and media 12
| Date | Title | Description | Source |
| 14.03.2024 | Rare Disease Advocates Learn to Accelerate Therapeutic Devel... | RARE Drug Development Symposium The RARE Drug Development Symposium, hosted by Global Genes and the ... | prweb.com/... |
| 08.03.2024 | Ovid Therapeutics Reports Business Updates, Fourth Quarter a... | - | globenewsw... |
| 09.02.2022 | Healx and Ovid Therapeutics enter strategic partnership | Healx and Ovid Therapeutics enter strategic partnership 09-02-2022 New York, NY and Cambridge, UK Ov... | cambridgen... |
| 05.06.2019 | New BIO chair hopes for greater policy focus on rare disease... | In an interview at the BIO conference in Philadelphia Wednesday, Levin said rare diseases will be a ... | medcitynew... |
| 05.05.2017 | Term Sheet — Friday, May 5 | CRYPTO-SPLAINING Last week a very confusing press release crossed my radar. It read: “The Argon Grou... | fortune.co... |
| 26.04.2017 | Term Sheet — Wednesday, April 26 | ET CETERA Good morning! This the third-largest ever “ed tech” deal, aside from German publishing gia... | fortune.co... |
| 13.05.2016 | Big Pharma Innovation in Small Places | As a vice president of the $38 billion (sales) French drug company Sanofi, Victoria Richon witnesse... | fortune.co... |
| 11.08.2015 | Ovid Therapeutics Completes $75M Series B Financing | Ovid Therapeutics Inc., a New York-based biopharmaceutical company focused on developing therapies f... | finsmes.co... |
| 11.08.2015 | Daily funding roundup - August 11, 2015 | Insight Venture Partners closed $4.75B; Kensington Capital closed $237M; Unify Square raised $4M Des... | vator.tv/n... |
| 25.03.2015 | Stealth neuroscience startup Ovid Therapeutics raises $5M fo... | The article continues: Levin is set to disclose more about the company in the next few weeks but for... | medcitynew... |
Show more